AstraZeneca picks up a friend for Tagrisso in $40M upfront deal

AstraZeneca is tossing a little cash towards Allorion Therapeutics to pick up a friend for approved lung cancer med Tagrisso.

The deal includes upfront and near-term milestones of $40 million, with development and commercial milestones of $500 million total possible, plus royalties, according to a Tuesday press release.